Notably, Ocaranza et al. showed that T2DM patients treated with glucose-lowering drugs, antihypertensive treatment and statins had a significant increase in ROCK activation in peripheral blood along with increased plasma angiotensin II and malondialdehyde (MDA) levels, and inhibiting the rock cascade might induce clinical benefits in heart failure with reduced ejection fraction (HFrEF) patients. The gene discussed is AGT; the disease is heart failure.